HeadWise Headache & Migraine News: FDA Approvals, Treatment Updates & More | March 2025
4 snips
Mar 19, 2025 Tim Smith, CEO of Study Metrics Research and a renowned headache specialist, dives into the latest breakthroughs in migraine treatment. He discusses the new FDA-approved medication Simbravo, which combines risotriptan and meloxicam for rapid relief. The conversation also covers Jernovix, a promising non-opioid painkiller, and its innovative mechanism. Smith explores how statins might play a role in pain management and highlights the intriguing connection between proton pump inhibitors and increased migraine frequency, along with the link between chronic migraines and pelvic pain in women.
AI Snips
Chapters
Transcript
Episode notes
New Migraine Drug Simbravo
- Simbravo, a new migraine drug, combines risatriptan (Maxalt) and meloxicam.
- The combination offers rapid pain relief and longer duration, similar to Treximet.
Non-Opioid Painkiller Zurnovic
- Zurnovic is a new non-opioid painkiller for acute pain, targeting peripheral nerves.
- It's shown similar effectiveness to opioids in post-operative pain management, offering a potential alternative.
Statins and Migraine
- Statin drugs, typically used for lowering cholesterol, might improve migraine.
- Studies suggest a potential link between statin use and migraine reduction, especially with higher vitamin D levels.